Demand of Microvascular Complications of Diabetes in US Industry : Technology, Applications, Growth and Status 2016-2022
Researchmoz added Most up-to-date research on "PharmaPoint: Microvascular Complications of Diabetes - US Drug Forecast and Market Analysis to 2022" to its huge collection of research reports.
(EMAILWIRE.COM, January 04, 2017 ) The entire market for microvascular complications of diabetes (MCD) diabetic nephropathy, retinopathy, and neuropathy is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.
The base-year market leader in the US is Roche/Novartis Lucentis, with $497m in sales, as the drug is the first-to-market anti-VEGF inhibitor approved for the treatment of DME. Lucentis will face stiff competition in Regeneron/Bayers Eylea, which is currently in Phase III trials for DME.
Scope
Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the US MCD market.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186886
Table of Content
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
3 Disease Overview 15
3.1 Etiology and Pathophysiology 17
3.1.1 Diabetic Nephropathy 17
3.1.2 Diabetic Retinopathy 19
3.1.3 Diabetic Neuropathy 20
3.2 Prognosis 21
3.3 Quality of Life 22
3.4 Symptoms 23
4 Disease Management 24
4.1 Treatment Overview 24
4.1.1 Diagnosis and Referrals 24
4.1.2 Screening 26
4.1.3 Treatment Guidelines 27
4.2 US 34
4.2.1 Diagnosis 34
4.2.2 Clinical Practice 36
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
The base-year market leader in the US is Roche/Novartis Lucentis, with $497m in sales, as the drug is the first-to-market anti-VEGF inhibitor approved for the treatment of DME. Lucentis will face stiff competition in Regeneron/Bayers Eylea, which is currently in Phase III trials for DME.
Scope
Overview of MCD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the US MCD market.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186886
Table of Content
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
3 Disease Overview 15
3.1 Etiology and Pathophysiology 17
3.1.1 Diabetic Nephropathy 17
3.1.2 Diabetic Retinopathy 19
3.1.3 Diabetic Neuropathy 20
3.2 Prognosis 21
3.3 Quality of Life 22
3.4 Symptoms 23
4 Disease Management 24
4.1 Treatment Overview 24
4.1.1 Diagnosis and Referrals 24
4.1.2 Screening 26
4.1.3 Treatment Guidelines 27
4.2 US 34
4.2.1 Diagnosis 34
4.2.2 Clinical Practice 36
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Contact Information:
Researchmoz Global Pvt.Ltd
Researchmoz
Tel: +1-518-621-2074
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Researchmoz Global Pvt.Ltd
Researchmoz
Tel: +1-518-621-2074
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results